Psychomotor Speed From Minimal Hepatic Encephalopathy Testing Is Associated With Physical Frailty in Patients With

Miguel Sogbe1, Randi Wong2, Pamela M Bloomer3

  • 1Liver Unit, Clinica Universidad de Navarra, Pamplona, Spain.

Abstract

Insights

Physical frailty, measured by the Liver Frailty Index (LFI), is associated with minimal hepatic encephalopathy (MHE) in advanced chronic liver disease (AdvCLD) patients. A simpler MHE diagnosis using the Stroop EncephalApp (StE) showed significant correlations with frailty.

Area of Science:

  • Hepatology
  • Neurology
  • Geriatrics

Background:

  • Physical frailty and minimal hepatic encephalopathy (MHE) are prevalent in advanced chronic liver disease (AdvCLD).
  • The standard Psychometric Hepatic Encephalopathy Score for MHE diagnosis is complex for routine clinical use.
  • The Stroop EncephalApp (StE) provides a simpler alternative for MHE diagnosis.

Purpose of the Study:

  • To investigate the association between MHE, diagnosed using the StE, and physical frailty, assessed by the Liver Frailty Index (LFI).
  • To explore the relationship between MHE and physical function in patients with AdvCLD.

Main Methods:

  • A multicenter study involving patients with AdvCLD awaiting liver transplantation.
  • Patients were grouped based on MHE presence (StE) and compared using LFI scores.
  • Spearman rank correlation and logistic regression analyzed factors influencing StE and MHE diagnosis.

Main Results:

  • 73% of 267 patients had MHE; 18% were frail.
  • Patients with MHE exhibited lower LFI scores and higher rates of pre-frailty or frailty.
  • Significant correlation found between StE off-time and LFI score (rho = 0.438, P < 0.001).
  • Multivariable analysis revealed LFI independently associated with MHE (OR 2.41, 95% CI 1.52-3.82).

Conclusions:

  • The LFI effectively captures the link between neurocognitive (psychomotor speed) and physical function in AdvCLD.
  • Findings highlight the interplay between MHE and physical frailty in this population.
  • Further research needed on interventions for cognitive and physical impairments to improve AdvCLD outcomes.

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
405
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
360
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
71